<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03970200</url>
  </required_header>
  <id_info>
    <org_study_id>IRB # 832962</org_study_id>
    <nct_id>NCT03970200</nct_id>
  </id_info>
  <brief_title>PMT for Severe-CDI</brief_title>
  <official_title>A Phase II, Randomized Trial to Evaluate the Safety and Efficacy of Fecal Microbiota Transplantation Using the Penn Microbiome Therapy Products for Severe or Severe-Complicated/Fulminant Clostridium Difficile Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open label, comparative, Phase II study to determine whether fecal&#xD;
      microbiota transplant using Penn Microbiome Therapy products helps standard therapy to treat&#xD;
      severe Clostridium difficile infection (C diff).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, open label, comparative</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with resolution of symptoms after treatment with one of the PMT suite of products.</measure>
    <time_frame>7 Days</time_frame>
    <description>The outcome will be satisfied when the subject is discharged from the hospital (not to hospice or palliative care) or, while the subject remains hospitalized, when the following criteria are met for 72 hours:&#xD;
If radiology study or studies performed, ileus/dilation/megacolon either not noted or noted as resolved&#xD;
Ileus/megacolon either noted as resolved by any provider documentation or not noted&#xD;
WBC&lt;15,000 cells/uL&#xD;
Serum creatinine decreased, unchanged, or increased by ≤0.2 mg/dL over 72 hours (if not receiving continuous renal replacement therapy (CRRT) or hemodialysis (HD))&#xD;
Lactate ≤2.2 mmol/L (if measured by clinical care team)&#xD;
No vasopressors used (including epinephrine, norepinephrine, phenylephrine, or vasopressin)&#xD;
Temperature &lt;38.5 °C and ≥35.6°C&#xD;
&lt; 8 bowel movements per day and &lt; 600 mL unformed stool (if volume recorded)&#xD;
Meeting fewer than 3 systemic inflammatory response syndrome (SIRS) criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE V5.0</measure>
    <time_frame>180 Days</time_frame>
    <description>All-cause mortality at 30- and 60-days following last FMT&#xD;
Colectomy or diverting ileostomy within 30 days after last FMT&#xD;
Cumulative days of hospitalization from enrollment until 30 days after FMT&#xD;
Cumulative days in intensive care unit from enrollment until 30 days after last FMT&#xD;
Bacteremia from enrollment until 30 days after last FMT&#xD;
Repeat hospital admission within 60 days of discharge from index hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency solicited adverse events (AEs) as assessed by CTCAE V5.0</measure>
    <time_frame>180 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency serious adverse events (SAEs) as assessed by CTCAE V5.0</measure>
    <time_frame>180 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of AEs of special interest (AESIs) as assessed by CTCAE V5.0</measure>
    <time_frame>180 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Severe Clostridium Difficile Infection</condition>
  <condition>Severe-Complicated/Fulminant Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>No investigational product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who receive the antibiotics usually prescribed for C diff infection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Upper gastrointestinal FMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who receive the antibiotics usually prescribed for C diff infection, along with PMT that is given by mouth in capsules or through a tube that goes into your stomach/intestines if you already have one (upper delivery). You will not be assigned to this group if you cannot take any medications either by mouth or through a tube safely, as determined by your doctor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lower gastrointestinal FMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who receive the antibiotics usually prescribed for C diff infection, along with PMT that is given through the rectum by an enema (lower delivery).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Penn Microbiome Therapy - 001</intervention_name>
    <description>Fecal Microbiota for Transplant, enema product</description>
    <arm_group_label>Lower gastrointestinal FMT</arm_group_label>
    <other_name>PMT-001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Penn Microbiome Therapy - 002</intervention_name>
    <description>Fecal Microbiota for Transplant, suspension product</description>
    <arm_group_label>Upper gastrointestinal FMT</arm_group_label>
    <other_name>PMT-002</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Penn Microbiome Therapy - 003</intervention_name>
    <description>Fecal Microbiota for Transplant, capsule product</description>
    <arm_group_label>Upper gastrointestinal FMT</arm_group_label>
    <other_name>PMT-003</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotics</intervention_name>
    <description>Standard of care antibiotics</description>
    <arm_group_label>Lower gastrointestinal FMT</arm_group_label>
    <arm_group_label>No investigational product</arm_group_label>
    <arm_group_label>Upper gastrointestinal FMT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. One or more episodes of CDI with symptoms including bowel movements altered in&#xD;
             frequency or consistency from baseline.&#xD;
&#xD;
          -  2. Stool test positive for Clostridium difficile by EIA by FDA-cleared assay within 7&#xD;
             days prior to enrollment.&#xD;
&#xD;
          -  3. Age ≥ 18 years&#xD;
&#xD;
          -  4. Meets any one of the listed criteria for severe or severe-complicated/fulminant&#xD;
             disease within 72 hours of enrollment.&#xD;
&#xD;
          -  5. Receiving antibiotic treatment for S/SC/F-CDI per current IDSA guidelines.&#xD;
&#xD;
        Enrollment criteria details:&#xD;
&#xD;
          -  1. Must either meet ≥1 criteria in severe category or in severe complicated category&#xD;
             to be enrolled&#xD;
&#xD;
          -  2. If the subject meets criteria in both categories, stratify to the higher severity&#xD;
             category (severe complicated)&#xD;
&#xD;
          -  3. Detailed enrollment criteria definitions:&#xD;
&#xD;
          -  a. WBC ≥15,000 cells/uL - if any value in the time period meets this definition&#xD;
&#xD;
          -  b. Hypotension with systolic blood pressure sustained &lt; 90mmHg for three or more hours&#xD;
             or requiring vasopressors (epinephrine, norepinephrine, phenylephrine, or vasopressin)&#xD;
&#xD;
          -  c. Acute kidney injury - increase in serum creatinine level by ≥50% or new dialysis&#xD;
             initiation&#xD;
&#xD;
          -  i. If a baseline serum creatinine value is not available, acute kidney injury will be&#xD;
             defined as a serum creatinine &gt;1.5 mg/dL&#xD;
&#xD;
          -  d. Temperature ≥38.5 °C or &lt;35.6°C - one value needed in time period -&#xD;
&#xD;
          -  e. Ileus, bowel dilation or megacolon&#xD;
&#xD;
          -  i. Ileus: If noted in any provider documentation or problem list (search words&#xD;
             &quot;ileus&quot;) OR&#xD;
&#xD;
          -  ii. If the words &quot;dilated&quot; &quot;dilation&quot; or &quot;ileus&quot; are noted in a radiology report on&#xD;
             intestines/colon, or if &quot;megacolon&quot; noted&#xD;
&#xD;
          -  f. Lactate &gt;2.2 mmol/L - if any value in the time period meets this definition&#xD;
&#xD;
          -  g. SIRS criteria&#xD;
&#xD;
          -  i. Heart rate &gt; 90 beats per minute&#xD;
&#xD;
          -  ii. Respiratory rate &gt; 20 breaths per minute or PaCO2 &lt; 32 mmHg&#xD;
&#xD;
          -  iii. Temperature &gt;38ºC or &lt;36ºC&#xD;
&#xD;
          -  iv. WBC &gt; 12,000 cells/uL, &lt;4,000 cells/uL, or &gt;10% immature (band) forms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Evidence of colon/small bowel perforation at the time of study screening.&#xD;
&#xD;
          -  2. Goals of care are directed to comfort rather than curative measures.&#xD;
&#xD;
          -  3. Moderate (ANC &lt; 1000 cells/uL) or severe (ANC &lt; 500 cells/uL) neutropenia.&#xD;
&#xD;
          -  4. Known food allergy that could lead to anaphylaxis.&#xD;
&#xD;
          -  5. Pregnancy&#xD;
&#xD;
          -  a. For subjects of childbearing potential (ages 18 to 55), the subject must have a&#xD;
             negative urine pregnancy test within 48 hours of consent and no more than 48 hours&#xD;
             prior to first product administration.&#xD;
&#xD;
          -  6 Receipt of FMT or enrollment in a clinical trial for FMT within the last 3 months.&#xD;
&#xD;
          -  7 COVID-19 infection, as defined by a positive nucleic acid or antigen test within the&#xD;
             prior 14 days and symptoms consistent with COVID-19 infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ebbing Lautenbach, MD, MPH, MSCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Infectious Diseases, Department of Medicine, University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brendan J Kelly, MD, MS</last_name>
    <phone>(215) 662-6932</phone>
    <email>brendank@pennmedicine.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lauren Dutcher, MD</last_name>
    <phone>(215) 662-6932</phone>
    <email>dutcherl@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital of the Univeristy of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brendan J Kelly, MD, MS</last_name>
      <phone>215-662-6932</phone>
      <email>brendank@pennmedicine.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Dutcher, MD</last_name>
      <phone>2156626932</phone>
      <email>dutcherl@pennmedicine.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ebbing Lautenbach, MD, MPH,MSCE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 17, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2019</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Enterocolitis, Pseudomembranous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

